On April 24, Minsheng Health (301507) released its 2023 annual performance report, which is also the first annual report after the company went public. Minsheng Health’s main products are used mainly for supplementing nutrients such as vitamins and minerals. The company operates in the dietary nutritional supplement industry. During the reporting period, Minsheng Health achieved operating income of approximately $91.34 million, an increase of 6.33% over the same period last year.
The net profit attributable to shareholders of listed companies was about $13.5 million, a year-on-year increase of 8.38%. In 2023, the revenue from the vitamin and mineral supplement series was around $89.49 million, a year-on-year increase of 7.39%. The Multivitamin Element Tablet (21) had a revenue of approximately $74.72 million, a year-on-year increase of 8.47%.
The revenue from multivitamin mineral tablets health food and food was around $12.09 million, a year-on-year increase of 19.71%. The income from other vitamins and minerals OTC products was approximately $2.51 million, a year-on-year decrease of 39.3%. In 2023, the revenue from the probiotics series was about $1 million, a year-on-year decrease of 55.99%.
From the perspective of gross profit margin, the gross profit margins for Multivitamin Element Tablet (21) and multivitamin mineral tablets health food and food were 68.80% and 37.76%, respectively. (Source: ShuZhengKangXun)
Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE
Visit HPA-China’s Information Hub, HERE